AVITA Medical, Inc. (RCEL) Market Cap
AVITA Medical, Inc. has a market capitalization of $107.6M.
Financials based on reported quarter end 2025-12-31
Price: $4.33
▼ -0.34 (-7.28%)
Market Cap: 107.57M
NASDAQ · time unavailable
CEO: Cary G. Vance
Sector: Healthcare
Industry: Medical - Devices
IPO Date: 2012-05-14
Website: https://www.avitamedical.com
AVITA Medical, Inc. (RCEL) - Company Information
Market Cap: 107.57M · Sector: Healthcare
AVITA Medical Inc. operates as a commercial-stage regenerative tissue company in the United States, Australia, and the United Kingdom. It offers regenerative products to address unmet medical needs in burn injuries, trauma injuries, chronic wounds, and dermatological and aesthetics indications, including vitiligo. The company's patented and proprietary platform technology provides treatment solutions derived from the regenerative properties of a patient's own skin. Its lead product is RECELL System, a device that enables healthcare professionals to produce a suspension of Spray-On Skin cells using a small sample of the patient's own skin for use in the treatment of acute thermal burns in patients eighteen years and older. The company has a research collaboration with the University of Colorado School of Medicine to establish pre-clinical proof-of-concept for a spray-on treatment of genetically corrected cells; and a research collaboration with Houston Methodist Research Institute to explore molecular reversal of cellular aging through a novel cell suspension delivery system. The company was formerly known as AVITA Therapeutics, Inc. and changed its name to AVITA Medical Inc. in December 2020. AVITA Medical Inc. was incorporated in 2000 and is based in Valencia, California.
Analyst Sentiment
Based on 7 ratings
Analyst 1Y Forecast: $5.83
Average target (based on 2 sources)
Consensus Price Target
Low
$4
Median
$7
High
$10
Average
$7
Potential Upside: 55.9%
Price & Moving Averages
Related Companies in Healthcare
NEURONETICS INC (STIM)
Healthcare
$0.11B
Mkt Cap
HUMACYTE INC (HUMA)
Healthcare
$0.11B
Mkt Cap
ALDEYRA THERAPEUTICS INC (ALDX)
Healthcare
$0.10B
Mkt Cap
BIOTE CORP CLASS A (BTMD)
Healthcare
$0.10B
Mkt Cap
DEFINITIVE HEALTHCARE CORP CLASS A (DH)
Healthcare
$0.12B
Mkt Cap
CARDIFF ONCOLOGY INC (CRDF)
Healthcare
$0.12B
Mkt Cap
Fundamentals Overview
📊 AI Financial Analysis
Powered by StockMarketInfo"RCEL reported revenues of $17.6M for the fiscal year ending December 31, 2025, but recorded a net loss of $11.6M, indicating ongoing profitability challenges. The company’s total assets stand at $56.4M against total liabilities of $73.0M, reflecting a negative equity of $16.7M and raising concerns about its balance sheet strength. Cash flow remains negative with operating cash flow at -$5.4M and free cash flow at -$3.7M, indicating difficulties in sustaining operational activities. The share price decreased by 58.8% over the past year, pointing to substantial market performance issues, despite a year-to-date gain of 10.66%. As no dividends have been paid, the focus remains on price appreciation, which is significantly negative. Overall, RCEL exhibits critical challenges in growth, profitability, and cash management, which need to be addressed for a healthy investment outlook."
Revenue Growth
Revenue of $17.6M shows modest growth potential but needs to improve.
Profitability
Negative net income highlights serious profitability issues.
Cash Flow Quality
Consistently negative cash flows raise concerns about sustainability.
Leverage & Balance Sheet
Negative equity and high liabilities pose significant risks.
Shareholder Returns
Significant decline in share price negatively impacts returns.
Analyst Sentiment & Valuation
Price targets suggest some analysts see potential, but overall sentiment is cautious.
Disclaimer:This analysis is AI-generated for informational purposes only. Accuracy is not guaranteed and this does not constitute financial advice.
Management framed Q4 as “control” rather than acceleration, citing reimbursement clarity restored by 6/7 MACs publishing ReCell payment rates and a shift to utilization/repeat use in ~200 burn/trauma centers. The hard numbers show margin pressure: Q4 gross margin 81.2% vs 87.6% prior year (inventory reserves + mix). Operating expenses improved (down 5% YoY; down 10% ex severance), and cash burn improved again (net cash use down to $5.1M in Q4). The biggest explicit mitigation was the January refinancing: covenant risk was engineered away, with a Q1 revenue “trigger” around $15.4M versus $17.6M Q4 and 2026 guidance of $80M–$85M. In the Q&A, analysts pressed on (1) what’s holding up the 7th MAC and (2) CoHiliX/PermeDerm attachment dynamics; management largely avoided specifics (no conversion-rate number) and relied on “steady rate” / administrative variability in VAC timelines. Overall tone was confident on execution, but the answers reveal ongoing process uncertainty (MAC #7 + VAC timing) behind the growth plan.
Growth Catalysts
- Normalization of ReCell utilization after reimbursement uncertainty resolution (accounts reengage)
- Expanded use of CoHiliX and PermeDerm within the core burn/trauma center base
- Multiproduct acute wound care adoption (ReCell + CoHiliX + PermeDerm used together on individual patients in early case experiences at Boswick)
- Increasing repeat use within ~200 burn and trauma centers rather than new-account wins
Business Development
- Engagement with all 7 Medicare Administrative Contractors (MACs) to restore ReCell reimbursement clarity (6/7 published payment rates as of call; 7th pending publication)
- Distributor-led approach in select European markets for ReCell Go following CE Mark approval (supported initial clinical use in a small number of European markets)
- VAC pathway: account “champions” for CoHiliX/PermeDerm guiding products through VAC and into department practice
Financial Highlights
- Q4 2025 revenue: $17.6M vs $18.4M prior-year period; described as stabilization and consistent with revised guidance
- Full-year 2025 revenue: ~$71.6M (+~11% vs 2024)
- Q4 gross margin: 81.2% vs 87.6% prior year (down due to inventory reserves and product mix)
- Full-year gross margin: 82.1% vs 85.8% in 2024 (inventory reserves; mix impact with increased CoHiliX/PermeDerm contribution)
- Q4 total operating expenses: $24.7M (down 5% YoY); excluding $1.2M one-time severance, operating expenses down 10% YoY
- Full-year operating expenses: declined 9% (down $10.4M) including nonrecurring severance
- Cash use improved for third consecutive quarter: net cash use $10.1M (Q2) -> $6.2M (Q3) -> $5.1M (Q4)
- Debt refinancing in January via Perceptive Advisors LLC; increased covenant headroom (see capital_funding) used to reduce constraint risk
Capital Funding
- Cash & marketable securities at quarter end: $18.2M
- Refinanced debt (January) into new credit facility with Perceptive Advisors LLC; interest-only, no amortization
- Revenue covenant: initial trailing twelve-month (TTM) requirement $68.5M; implies only ~$15.4M revenue in Q1 to not trigger covenant
- 2026 TTM revenue requirement $73.0M; stated as aligned below 2026 revenue guidance ($80M–$85M)
- Minimum cash covenant reduced from $10.0M to $5.0M
- Optional incremental capital available if certain revenue milestone is met
Strategy & Ops
- Commercial focus refined to utilization in core burn and trauma centers
- Shift away from bulk ordering toward more organic monthly usage patterns
- Operational model described as more disciplined with improved visibility into cash use and clearer understanding of customer adoption/usage
- One-time severance: $1.2M in Q4 2025 (nonrecurring)
Market Outlook
- 2026 full-year revenue guidance: $80M to $85M (+~12% to +~19% vs 2025)
- Guidance commentary in Q&A: management expects progressive growth/gradual acceleration through the year (no quarterly guidance); Q4 should normalize/flatten ordering patterns as a starting point
- Reimbursement pathway outlook: management does not expect further disruptions beyond continued work through the MACs in coming months
Risks & Headwinds
- Reimbursement uncertainty impacted utilization throughout 2025; as of the call 6/7 MACs have published payment rates for ReCell procedures
- MAC #7 still pending publication (management provided no quantified risk; stated “no reason to be concerned” and “highly engaged” with no administrative certainty on timing)
- VAC process timing variability creates lead time risk (no set time; depends on account administrative process)
- Gross margin headwind in 2025 from inventory reserves and product mix; additional CoHiliX/PermeDerm mix lowers reported % margin though incremental gross profit without commensurate operating-expense increases
Sentiment: CAUTIOUS
Note: This summary was synthesized by AI from the RCEL Q4 2025 earnings transcript. Financial data is complex; please verify all metrics against official SEC filings before making investment decisions.